March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patie ...

Fortrea forecasts revenue and EBITDA declines for 2025. With a $477.16M market cap, financial improvement could drive stock ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best ...

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until ...

ImmunityBio, Inc.'s FDA rejection for ANKTIVA impacts IBRX shares. Explore the market reaction, potential catalysts, and ...